Neurocrine Biosciences Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
SPRB | F | Spruce Biosciences, Inc. | -1.57 | |
NBIX | C | Neurocrine Biosciences, Inc. | 0.52 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
PBE | C | PowerShares Dynamic Biotech & Genome | 4.18 | |
MNTL | D | Tema Neuroscience and Mental Health ETF | 4.17 | |
IBRN | C | iShares Neuroscience and Healthcare ETF | 3.61 | |
FBT | C | First Trust Amex Biotech Index Fund | 3.59 | |
XBI | D | SPDR S&P Biotech ETF | 2.62 |
Compare ETFs
Related Industries:
Biotechnology
- Neurocrine Biosciences
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
Recent Comments
- TraderMike on BOOT
- Dr_Duru on BOOT
- TraderMike on Stochastic Reached Oversold
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
From the Blog
Featured Articles